The European stock markets have shown resilience, with the pan-European STOXX Europe 600 Index reaching new highs amid strong corporate earnings and renewed interest in AI-related stocks. In this context, penny stocks—often representing smaller or newer companies—continue to capture investor interest due to their potential for significant returns. Although the term 'penny stock' might seem outdated, these investments can still uncover hidden value when focused on companies with solid financials and growth potential.
Below we spotlight a couple of our favorites from our exclusive screener.
Faes Farma (BME:FAE)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Faes Farma, S.A. is engaged in the research, development, production, and marketing of pharmaceutical products, healthcare products, and raw materials on an international scale with a market cap of €1.41 billion.
Operations: No specific revenue segments are reported for Faes Farma, S.A.
Market Cap: €1.41B
Faes Farma, S.A. recently reported a half-year sales increase to €382.9 million, up from €296.16 million the previous year, with net income rising to €56.88 million. Despite stable weekly volatility and no significant shareholder dilution over the past year, its earnings growth has been negative at -20.1%, contrasting with industry averages. The company's dividend yield of 3.95% is not well covered by free cash flows, though earnings are forecasted to grow by 15.96% annually moving forward. Faes Farma's debt is well managed with operating cash flow covering it effectively and short-term assets exceeding liabilities significantly.
- Dive into the specifics of Faes Farma here with our thorough balance sheet health report.
- Gain insights into Faes Farma's future direction by reviewing our growth report.
Greenland Resources (DB:M0LY)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Greenland Resources Inc. is a mining company focused on acquiring, exploring, and developing mineral projects in Greenland with a market cap of €102.90 million.
Operations: Greenland Resources Inc. currently does not report any revenue segments.
Market Cap: €102.9M
Greenland Resources Inc., with a market cap of €102.90 million, remains pre-revenue and unprofitable, reporting a net loss of CAD 7.51 million for the year ended March 2026. The company benefits from strong governmental support, with a non-repayable contribution of $7 million from Canada's CMRDD program to advance its Malmbjerg project in Greenland. This initiative includes innovative metallurgical programs targeting magnesium and rare earth elements recovery. Additionally, Greenland Resources has joined the BOREAS project to develop autonomous robotic systems for mining operations, supported by an EU grant of EUR 489,125 (CAD 800,000).
- Get an in-depth perspective on Greenland Resources' performance by reading our balance sheet health report here.
- Gain insights into Greenland Resources' past trends and performance with our report on the company's historical track record.
AFYREN SAS (ENXTPA:ALAFY)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: AFYREN SAS is a French company that offers biobased products as alternatives to petroleum-based molecules, with a market capitalization of €75.98 million.
Operations: The company generates revenue primarily from its Chemicals segment, amounting to €2.27 million.
Market Cap: €75.98M
AFYREN SAS, with a market cap of €75.98 million, is navigating the challenges typical of penny stocks. The company recently resumed operations at its AFYREN NEOXY plant following a planned technical shutdown aimed at performance improvements, suggesting potential production acceleration later in 2026. Despite being unprofitable with negative return on equity and minimal revenue (€2.27 million), AFYREN maintains a stable financial position with short-term assets significantly exceeding liabilities and no recent shareholder dilution. Analysts project significant stock price growth, yet profitability remains elusive over the next three years amidst ongoing volatility in share price movements.
- Take a closer look at AFYREN SAS' potential here in our financial health report.
- Gain insights into AFYREN SAS' outlook and expected performance with our report on the company's earnings estimates.
Taking Advantage
- Jump into our full catalog of 303 European Penny Stocks here.
- Searching for a Fresh Perspective? The end of cancer? These 33 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com